Public consultation: New classification of L01XC Monoclonal antibodies
Published Wednesday April 28 2021

New classification of L01XC Monoclonal antibodies

A revision of the classification of monoclonal antibodies for antineoplastic treatment, L01XC Monoclonal antibodies, is needed due to the increasing number of new monoclonal antibodies being developed in the field of cancer therapy. A revision of the current classification in L01XC was discussed by the WHO International Working Group for Drug Statistics Methodology at the latest meeting in March 2021. The Working Group would like feedback from the users of the ATC/DDD system of the proposed new classification to ensure that the new classification is useful.

New ATC 3^rd level L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

A new ATC 3^rd level L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES with 8 new ATC 4^th levels are proposed - see the proposal here. The substances are divided in subgroups according to their molecular target.  All monoclonal antibodies in L01XC will be included in the new ATC 3^rd level, L01F. Antibody Drug Conjugates for antineoplastic treatment are included in the new ATC 3^rd level. The proposed new classification is intended to be implemented in the ATC Index 2022.

Deadline 1^st of September 2021

We would appreciate your feedback related to the new proposed classification. If you have alternative suggestions for ATC classification, or if you consider the new classification not appropriate for drug utilization purposes, we would appreciate your comments.

We will appreciate any comments you may have as soon as possible and not later than 1^st of September 2021.

Proposal for re-classification of L01XC Monoclonal antibodies.

Please send your comments to .